Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Pancreatic Cancer Detection Consortium

NCT06388967 · View on ClinicalTrials.gov ↗

Study Summary

This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

Interventions

  • DIAGNOSTIC_TEST PANcreatic cancer Exosome Early detectiON (PANXEON)

Study Locations (11)

Arizona

  • Translational Genomics Research Institute — Phoenix
  • Honorhealth — Scottsdale

California

  • City of Hope Medical Center — Monrovia
  • Hoag Center — Newport Beach

Other

  • Nagoya University — Nagoya
  • Asan Medical Center — Seoul

Illinois

  • OSF HealthCare — Peoria

Louisiana

  • Ochsner Medical Center — Jefferson

New Jersey

  • Atlantic Health System — Morristown

South Carolina

  • Piedmont Medical Center — Rock Hill

Wisconsin

  • Medical College of Wisconsin — Milwaukee

Trial Details

FieldValue
Enrollment Target 2,000 participants
Start Date 2023-03-15
Est. Completion 2026-06-18

Sponsor

City of Hope Medical Center

771 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06388967

The ClinicalTrials.gov registry entry for NCT06388967 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 771 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 10 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention — of which PANcreatic cancer Exosome Early detectiON (PANXEON) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06388967 reports 11 study locations spanning 8 distinct geographic areas — top geographies include Arizona, California, Other. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06388967 about?

NCT06388967 is a clinical study titled "Pancreatic Cancer Detection Consortium". This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

What is the current status of trial NCT06388967?

This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2023-03-15. Estimated completion is 2026-06-18.

What conditions does trial NCT06388967 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06388967?

The interventions under investigation include: PANcreatic cancer Exosome Early detectiON (PANXEON) (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06388967?

This trial is sponsored by City of Hope Medical Center, which has 771 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06388967 being conducted?

This trial has 11 study locations across Arizona, California, Illinois, Louisiana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial